vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and Life Time Group Holdings, Inc. (LTH). Click either name above to swap in a different company.
Life Time Group Holdings, Inc. is the larger business by last-quarter revenue ($745.1M vs $598.7M, roughly 1.2× EXELIXIS, INC.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 16.5%, a 24.3% gap on every dollar of revenue. On growth, Life Time Group Holdings, Inc. posted the faster year-over-year revenue change (12.3% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $-64.6M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 11.7%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Life Time Group Holdings, Inc. operates a network of premium athletic, fitness and wellness destinations across the United States. It offers diverse services including state-of-the-art gym facilities, group exercise classes, personal training, spa treatments, nutrition coaching, youth programs and co-working spaces for consumers pursuing holistic healthy lifestyles.
EXEL vs LTH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $745.1M |
| Net Profit | $244.5M | $123.0M |
| Gross Margin | 95.6% | 49.1% |
| Operating Margin | 39.3% | 17.4% |
| Net Margin | 40.8% | 16.5% |
| Revenue YoY | 5.6% | 12.3% |
| Net Profit YoY | 74.8% | 231.0% |
| EPS (diluted) | $0.89 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $745.1M | ||
| Q3 25 | $568.3M | $782.6M | ||
| Q2 25 | $555.4M | $761.5M | ||
| Q1 25 | $566.8M | $706.0M | ||
| Q4 24 | — | $663.3M | ||
| Q3 24 | $539.5M | $693.2M | ||
| Q2 24 | $637.2M | $667.8M |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $123.0M | ||
| Q3 25 | $184.8M | $102.4M | ||
| Q2 25 | $159.6M | $72.1M | ||
| Q1 25 | $139.9M | $76.1M | ||
| Q4 24 | — | $37.2M | ||
| Q3 24 | $118.0M | $41.4M | ||
| Q2 24 | $226.1M | $52.8M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | 49.1% | ||
| Q3 25 | 96.6% | 47.1% | ||
| Q2 25 | 96.5% | 47.0% | ||
| Q1 25 | 96.5% | 47.5% | ||
| Q4 24 | — | 48.2% | ||
| Q3 24 | 96.8% | 46.5% | ||
| Q2 24 | 97.2% | 46.8% |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 17.4% | ||
| Q3 25 | 37.6% | 17.3% | ||
| Q2 25 | 33.6% | 14.2% | ||
| Q1 25 | 28.8% | 15.2% | ||
| Q4 24 | — | 13.1% | ||
| Q3 24 | 25.2% | 13.5% | ||
| Q2 24 | 43.3% | 15.7% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | 16.5% | ||
| Q3 25 | 32.5% | 13.1% | ||
| Q2 25 | 28.7% | 9.5% | ||
| Q1 25 | 24.7% | 10.8% | ||
| Q4 24 | — | 5.6% | ||
| Q3 24 | 21.9% | 6.0% | ||
| Q2 24 | 35.5% | 7.9% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $0.55 | ||
| Q3 25 | $0.65 | $0.45 | ||
| Q2 25 | $0.55 | $0.32 | ||
| Q1 25 | $0.47 | $0.34 | ||
| Q4 24 | — | $0.17 | ||
| Q3 24 | $0.40 | $0.19 | ||
| Q2 24 | $0.77 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $204.8M |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $2.2B | $3.1B |
| Total Assets | $2.8B | $8.0B |
| Debt / EquityLower = less leverage | — | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $204.8M | ||
| Q3 25 | $791.1M | $218.9M | ||
| Q2 25 | $1.0B | $175.5M | ||
| Q1 25 | $1.1B | $59.0M | ||
| Q4 24 | — | $10.9M | ||
| Q3 24 | $1.2B | $120.9M | ||
| Q2 24 | $1.0B | $34.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.8B |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $3.1B | ||
| Q3 25 | $2.0B | $3.0B | ||
| Q2 25 | $2.1B | $2.9B | ||
| Q1 25 | $2.2B | $2.7B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | $2.3B | $2.6B | ||
| Q2 24 | $2.1B | $2.4B |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $8.0B | ||
| Q3 25 | $2.7B | $7.8B | ||
| Q2 25 | $2.8B | $7.6B | ||
| Q1 25 | $2.9B | $7.3B | ||
| Q4 24 | — | $7.2B | ||
| Q3 24 | $3.0B | $7.2B | ||
| Q2 24 | $2.8B | $7.1B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.53× | ||
| Q1 25 | — | 0.56× | ||
| Q4 24 | — | 0.59× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 0.78× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $239.9M |
| Free Cash FlowOCF − Capex | $332.4M | $-64.6M |
| FCF MarginFCF / Revenue | 55.5% | -8.7% |
| Capex IntensityCapex / Revenue | 0.2% | 40.9% |
| Cash ConversionOCF / Net Profit | 1.36× | 1.95× |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $-21.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $239.9M | ||
| Q3 25 | $49.0M | $251.1M | ||
| Q2 25 | $211.4M | $195.7M | ||
| Q1 25 | $240.3M | $183.9M | ||
| Q4 24 | — | $163.1M | ||
| Q3 24 | $271.3M | $151.1M | ||
| Q2 24 | $119.5M | $170.4M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $-64.6M | ||
| Q3 25 | $46.2M | $28.6M | ||
| Q2 25 | $208.5M | $-26.3M | ||
| Q1 25 | $236.3M | $41.4M | ||
| Q4 24 | — | $26.8M | ||
| Q3 24 | $263.1M | $64.0M | ||
| Q2 24 | $113.0M | $26.1M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | -8.7% | ||
| Q3 25 | 8.1% | 3.7% | ||
| Q2 25 | 37.5% | -3.5% | ||
| Q1 25 | 41.7% | 5.9% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | 48.8% | 9.2% | ||
| Q2 24 | 17.7% | 3.9% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 40.9% | ||
| Q3 25 | 0.5% | 28.4% | ||
| Q2 25 | 0.5% | 29.2% | ||
| Q1 25 | 0.7% | 20.2% | ||
| Q4 24 | — | 20.6% | ||
| Q3 24 | 1.5% | 12.6% | ||
| Q2 24 | 1.0% | 21.6% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 1.95× | ||
| Q3 25 | 0.27× | 2.45× | ||
| Q2 25 | 1.32× | 2.71× | ||
| Q1 25 | 1.72× | 2.41× | ||
| Q4 24 | — | 4.39× | ||
| Q3 24 | 2.30× | 3.65× | ||
| Q2 24 | 0.53× | 3.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
LTH
| Membership | $535.1M | 72% |
| In Center | $191.2M | 26% |
| Other | $18.8M | 3% |
